Relationship of Leishmania RNA Virus (LRV) and Treatment Failure in Clinical Isolates of Leishmania Major

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2020 Mar 18

PMID 32178715

Citations 14

Authors

Mohsen Abtahi

Gilda Eslami

Serena Cavallero

Mahmood Vakili

Saeedeh Sadat Hosseini

Salman Ahmadian

Mohammad Javad Boozhmehrani

Ali Khamesipour

Affiliations

Soon will be listed here.

Abstract

Objective: Leishmaniasis is caused by different Leishmania spp. Treatment failure (TF) of cutaneous leishmaniasis (CL) is a serious issue that may be due to various reasons, previous studies suggested Leishmania RNA virus (LRV) as a potential cause of TF. Two variant groups of LRV1 and LRV2 are reported. In this study, the presence of LRV1/LRV2 was compared in TF with treatment response (TR) isolates of L. major. Clinical isolates of 15 TF and 15 TR were collected from CL patients referred to the Health Centers of Isfahan. Genomic DNA was extracted to identify Leishmania spp. using ITS1-PCR-RFLP. Identification of LRV1/LRV2 was performed using SYBR Green Real-Time PCR. The statistical analysis to test relationship between the treatment response with Glucantime and the presence of LRV were performed using SPSS 16.0 with Fisher's Exact test. P value of less than 0.05 was considered significant.

Results: ITS1-PCR-RFLP results showed that every isolate was identified as L. major. The results showed no LRV1 in any of the samples but 7 TR isolates and 2 TF isolates showed positive for LRV2. Statistical analysis showed no significant difference between the presence of LRV2 and response to Glucantime (p-value = 0.1086). Therefore, other mechanisms might be responsible for TF.

Citing Articles

Detection of Leishmania RNA Virus 2 (LRV2) among Clinical Isolates of Leishmania Major in Four Endemic Regions of Iran.

Mazaherifar S, Erfanian S, Solhjoo K, Roustazadeh A, Darayesh M, Taghipour A Acta Parasitol. 2024; 69(4):2046-2050.

PMID: 39190281 DOI: 10.1007/s11686-024-00915-x.

Systematic Review of Treatment Failure and Clinical Relapses in Leishmaniasis from a Multifactorial Perspective: Clinical Aspects, Factors Associated with the Parasite and Host.

de Almeida Santos G, Sousa J, Aguiar A, Torres K, Coelho A, Ferreira A Trop Med Infect Dis. 2023; 8(9).

PMID: 37755891 PMC: 10534360. DOI: 10.3390/tropicalmed8090430.

Accuracy of serological tests in diagnosing mucosal leishmaniasis.

Oliveira D, Lopes K, Avelar D, Cota G, Oliveira E Parasitol Res. 2023; 122(9):2001-2010.

PMID: 37391643 DOI: 10.1007/s00436-023-07900-9.

Leishmania RNA Virus Is Not Detected in All Species of the Leishmania Viannia Subgenus: The Case of L. (V.) panamensis in Colombia.

Rosales-Chilama M, Y Oviedo M, K Quintero Y, L Fernandez O, Gomez M Am J Trop Med Hyg. 2023; 108(3):555-560.

PMID: 36716739 PMC: 9978567. DOI: 10.4269/ajtmh.22-0551.

Multiple Regulations of Parasitic Protozoan Viruses: A Double-Edged Sword for Protozoa.

Zhao Z, Li X, Zhang N, Li J, Zhao N, Gao M mBio. 2023; 14(1):e0264222.

PMID: 36633419 PMC: 9973342. DOI: 10.1128/mbio.02642-22.

References

Torres-Guerrero E, Quintanilla-Cedillo M, Ruiz-Esmenjaud J, Arenas R . Leishmaniasis: a review. F1000Res. 2017; 6:750. PMC: 5464238. DOI: 10.12688/f1000research.11120.1. View

Ahmadian S, Eslami G, Fatahi A, Hosseini S, Vakili M, Ajamein Fahadan V . - and - expression in clinical no response-antimonial isolates. J Parasit Dis. 2019; 43(1):39-45. PMC: 6423244. DOI: 10.1007/s12639-018-1052-5. View

Singh N, Kumar M, Singh R . Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med. 2012; 5(6):485-97. DOI: 10.1016/S1995-7645(12)60084-4. View

Hejazi H, Eslami G, Dalimi A . The parasiticidal effect of electricity on Leishmania major, both in vitro and in vivo. Ann Trop Med Parasitol. 2004; 98(1):37-42. DOI: 10.1179/136485913X13789813917661. View

Hajjaran H, Mahdi M, Mohebali M, Samimi-Rad K, Ataei-Pirkooh A, Kazemi-Rad E . Detection and molecular identification of leishmania RNA virus (LRV) in Iranian Leishmania species. Arch Virol. 2016; 161(12):3385-3390. DOI: 10.1007/s00705-016-3044-z. View

Kleschenko Y, Grybchuk D, Matveeva N, Macedo D, Ponirovsky E, Lukashev A . Molecular Characterization of in from Uzbekistan. Genes (Basel). 2019; 10(10). PMC: 6826456. DOI: 10.3390/genes10100830. View

Ives A, Ronet C, Prevel F, Ruzzante G, Fuertes-Marraco S, Schutz F . Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science. 2011; 331(6018):775-8. PMC: 3253482. DOI: 10.1126/science.1199326. View

Widmer G, Dooley S . Phylogenetic analysis of Leishmania RNA virus and Leishmania suggests ancient virus-parasite association. Nucleic Acids Res. 1995; 23(12):2300-4. PMC: 307021. DOI: 10.1093/nar/23.12.2300. View

Zangger H, Ronet C, Desponds C, Kuhlmann F, Robinson J, Hartley M . Detection of Leishmania RNA virus in Leishmania parasites. PLoS Negl Trop Dis. 2013; 7(1):e2006. PMC: 3542153. DOI: 10.1371/journal.pntd.0002006. View

10.

Adaui V, Lye L, Akopyants N, Zimic M, Llanos-Cuentas A, Garcia L . Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania braziliensis in Peru and Bolivia. J Infect Dis. 2015; 213(1):112-21. PMC: 4676543. DOI: 10.1093/infdis/jiv354. View

11.

de Carvalho R, Lima-Junior D, da Silva M, Dilucca M, Rodrigues T, Horta C . Publisher Correction: Leishmania RNA virus exacerbates Leishmaniasis by subverting innate immunity via TLR3-mediated NLRP3 inflammasome inhibition. Nat Commun. 2020; 11(1):203. PMC: 6944679. DOI: 10.1038/s41467-019-13900-0. View

12.

Eslami G, Zarchi M, Moradi A, Hejazi S, Sohrevardi S, Vakili M . gene expression in antimony resistance and susceptible isolates. J Vector Borne Dis. 2016; 53(4):370-374. View

13.

Bourreau E, Ginouves M, Prevot G, Hartley M, Gangneux J, Robert-Gangneux F . Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse. J Infect Dis. 2015; 213(1):105-11. DOI: 10.1093/infdis/jiv355. View

14.

Ponte-Sucre A, Gamarro F, Dujardin J, Barrett M, Lopez-Velez R, Garcia-Hernandez R . Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017; 11(12):e0006052. PMC: 5730103. DOI: 10.1371/journal.pntd.0006052. View

15.

Parmentier L, Cusini A, Muller N, Zangger H, Hartley M, Desponds C . Severe Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient Coinfected with Leishmania braziliensis and Its Endosymbiotic Virus. Am J Trop Med Hyg. 2016; 94(4):840-843. PMC: 4824227. DOI: 10.4269/ajtmh.15-0803. View

16.

Hartley M, Bourreau E, Rossi M, Castiglioni P, Eren R, Prevel F . Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A. PLoS Pathog. 2016; 12(9):e1005852. PMC: 5033371. DOI: 10.1371/journal.ppat.1005852. View

17.

Ajamein V, Eslami G, Ahmadian S, Khamesipour A, Elloumi M . Gene expression of RNAP II, JBP1 and JBP2 in Leishmania major exposed to antimonials, amphotericin B and paromomycin. Ann Parasitol. 2018; 64(3):181-187. DOI: 10.17420/ap6403.149. View

18.

Zangger H, Hailu A, Desponds C, Lye L, Akopyants N, Dobson D . Leishmania aethiopica field isolates bearing an endosymbiontic dsRNA virus induce pro-inflammatory cytokine response. PLoS Negl Trop Dis. 2014; 8(4):e2836. PMC: 3998932. DOI: 10.1371/journal.pntd.0002836. View

19.

Cadd T, Keenan M, Patterson J . Detection of Leishmania RNA virus 1 proteins. J Virol. 1993; 67(9):5647-50. PMC: 237969. DOI: 10.1128/JVI.67.9.5647-5650.1993. View

20.

Alvar J, Velez I, Bern C, Herrero M, Desjeux P, Cano J . Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7(5):e35671. PMC: 3365071. DOI: 10.1371/journal.pone.0035671. View